Exalgo revenue was less 10 days of potential sales as explained. This coming Qtr should
yield a increase in sales in turn recieving a larger percentage of revenue.
I know Z944 is very important, but there is only one drug Z160 that will have results in 3rd qtr
2013 which will make or break us investors. I own enough shares that each penny equals 1K
up or down so I understand the concern. Long term holders will be rewarded in dollars not
I feel good about the progress of Z160 and confident of acceptance. One primary factor to me is
the amount of shares Chris Gallen has left on the table 1,842,986 or $3,317,374 when he could
of sold in early September at a $1.80. I am sure he is in the know on a frequent basis.
What person would gamble away that type of cash unless he was 100 percent positive of FDA acceptance? I believe he has been involved on a prior drug from start thru FDA approval.
this is certainly a stock for the iron stomach and patience. From the presentation, I feel that Justin is hinting that a Z944 release is imminent, most likely a parterner deal. "as of now Dr Corrigan is working with the experts..." and "being conscious" about deploying investor's money